Emyria Limited is a company focused on developing data-backed drug treatments and clinical care solutions, with a significant emphasis on mental health innovation. The company’s operations span across conducting clinical trials, developing novel drug compounds, and establishing purpose-built clinics for drug-assisted therapies.
Their leading research includes evaluating MDMA-Assisted Therapy for PTSD, alongside exploring the potential of MDMA-like compounds for broader neurological conditions. Emyria aims to address the urgent demand for innovative mental health treatments through evidence-based, scalable healthcare solutions.
Activities
B2B
Compounds of Interest
MDMA
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates